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Adding thiazide to a renin–angiotensin blocker
improves left ventricular relaxation and improves
heart failure in patients with hypertension
Hiroshi Ito1, Katsuhisa Ishii2, Hajime Kihara3, Noriaki Kasayuki4, Fumiaki Nakamura5, Kenei Shimada6,
Shota Fukuda7, Katsuomi Iwakura8 and Junichi Yoshikawa9, for Effect of ARB/Diuretics on Diastolic Function
in Patients with Hypertension (EDEN) trial investigators
Hypertension is associated with an increased risk of diastolic dysfunction. Angiotensin-converting enzyme inhibitors (ACEi)
and angiotensin receptor blockers (ARB) have failed to show improvement in clinical outcomes for patients with diastolic
dysfunction. In this study, we investigated the effect of changing an ACEi or ARB to a combination of losartan and
hydrochlorothiazide (HCTZ) on left ventricular (LV) preload and relaxation in patients with hypertension and diastolic
dysfunction. We enrolled 371 hypertensive patients with diastolic dysfunction who had not achieved their treatment goals with
an ACEi or ARB. We switched the ACEi or ARB to losartan/HCTZ and followed the patients for 24 weeks. The primary end points
were changes in septal mitral annular velocity during diastole (e¢) and in the ratio of mitral inﬂow velocity to e¢ velocity (E/e¢
ratio) from baseline to the end of follow-up. Mean systolic and diastolic blood pressures (BP) decreased by 22 and 11mmHg,
respectively, after changing from an ACEi or ARB to losartan/HCTZ. The e¢ velocity increased, and the E/e¢ ratio and brain
natriuretic peptide level decreased signiﬁcantly. High-sensitivity C-reactive protein also decreased signiﬁcantly (0.50 vs.
0.29mgdl 1, Po0.0001). There were only slight or no changes in glucose levels, homeostasis model assessment insulin
resistance (HOMA-R), uric acid and electrolytes after the drug change. Changing from an ACEi or ARB to losartan/HCTZ is
associated with a reduction in BP, improvement in LV relaxation, improvement in heart failure state and attenuation of systemic
inﬂammation with few adverse effects in patients with hypertension and diastolic dysfunction.
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INTRODUCTION
Diastolic dysfunction is the most common cause of heart failure (HF)
in patients with hypertension.1 Diastolic HF is associated with con-
siderable morbidity and mortality, and the risk of adverse outcomes
increases with the severity of diastolic dysfunction.2 Patients with
diastolic dysfunction have increased activation of the renin–angioten-
sin–aldosterone system, as do patients with systolic HF, which con-
tributes to the pathogenesis and progression of the condition.
However, angiotensin-converting enzyme inhibitors (ACEi) and
angiotensin receptor blockers (ARB) have failed to show a beneﬁt
with regard to mortality or morbidity.3–5 Thiazide is useful for
reducing volume load in patients with diastolic dysfunction.6 How-
ever, thiazide monotherapy has not been widely used in patients with
diastolic dysfunction. Decreases in blood pressure (BP) are blunted by
hypovolemia-induced activation of the renin–angiotensin–aldosterone
system. Thiazide monotherapy involves risks of dysglycemia and/or
dyslipidemia, and of elevation of C-reactive protein (CRP).7 To resolve
these problems, a small dose of thiazide in combination with an ACEi
or ARB is given to allow for the full antihypertensive effect of thiazide
and to minimize its adverse effects. However, it remains unknown
whether this combination therapy can improve diastolic function or
HF state and, if so, which factor has the principal role in the
improvement of HF: reduction in left ventricular (LV) pre-load,
improvement in its relaxation or both.
To answer these questions, we conducted a prospective, multi-
center study to test the hypothesis that changing from an ACEi or ARB
to losartan/hydrochlorothiazide (HCTZ) can improve LV diastolic
function in patients with hypertension and diastolic dysfunction.
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www.nature.com/hrThe aims of this study were (1) to elucidate the impact of changing
from an ACEi or ARB to losartan/HCTZ on LV preload, relaxation
and severity of HF; (2) to determine the responders and non-
responders to combination therapy; and (3) to determine the impact
of this drug change on the metabolism of glucose, lipids, uric acid,
electrolytes and CRP.
METHODS
Study population
Men and women from 20 to 80 years of age, with a history of stage 1 or 2
essential hypertension (mean BP measurement of 4140mmHg systolic or
490mmHg diastolic), who were receiving treatment with an ACEi or ARB,
were screened for inclusion by assessing their systolic and diastolic functions
with echocardiography. Mitral annular relaxation velocity of p8cms  1 was
used to make a diagnosis of diastolic dysfunction. The exclusion criteria were
an LV ejection fraction of o50%, septal mitral annular relaxation velocity
48cms  1, receiving treatment with diuretics and atrial ﬁbrillation at baseline.
The study protocol was approved by individual sites and written informed
consent was obtained from all patients before any study procedures.
Study protocol
The patients were followed at least for 4 weeks to observe that target BP, o130/
80mmHg, was not achieved with an ACEi or ARB. All patients underwent
echocardiographic screening for systolic and diastolic functions before the start
of treatment with losartan 50mg/hydrochlorothiazide 12.5mg. Then, the
administration of ACEi or ARB was stopped, and ACEi or ARB was replaced
with losartan/HCTZ. No other medications were changed throughout the
study period. BP and heart rate were measured in a sitting position at each
study visit. The adequacy of anti-hypertensive therapy was determined on the
basis of measured BP. The use of concomitant antihypertensive medication was
recorded at each study visit. If BP was not adequately controlled, add-on
treatment other than diuretics was considered, but such subjects were dropped
from this study. Patients were assessed at 4–8-week intervals for at least 24
weeks and underwent echocardiographic assessment at the end of the study.
Blood and urine tests were also performed at baseline and at the end of
the study.
Echocardiographic data analysis
From the mitral ﬂow velocity pattern, we measured the peak velocities of E and
Awaves on mitral ﬂow velocity, the ratio of their peak velocities (E/A ratio), the
isovolumic relaxation time (IVRT) and the deceleration time of the E wave.
Spectral pulsed-wave Doppler tissue interrogation of longitudinal mitral
annular velocity was recorded throughout the cardiac cycle at the septal
annulus in the apical four-chamber view. The peaks of apically directed systolic
(s¢ velocity) and early diastolic (e¢ velocity) myocardial velocities were mea-
sured. Additional exploratory analyses included changes in chamber dimen-
sions and the LV ejection fraction. LV mass was measured by using the
American Society of Echocardiography-recommended formula and the end-
systolic left atrial volume was measured by using the ellipsoid model.8 Both
values were indexed with body surface area in m2.
The primary endpoints were changes in e¢ velocity and in the ratio of mitral
inﬂow velocity to e¢ velocity (E/e¢ ratio) from baseline to follow-up. The
secondary efﬁcacy measures included differences in changes in BP, heart rate,
wall thickness, the LV mass index and the left atrial volume index from baseline
to follow-up. Blood samples were collected for measurements of brain
natriuretic peptide (BNP) and high-sensitivity CRP (hsCRP), along with
additional exploratory blood analyses, and urine was collected for measurement
of albumin concentrations.
Statistical analysis
All of the results are expressed as the mean±s.d. or proportions (%). Student’s
t-test was used for parametric data when a normal distribution and equal
dispersion were recognized. The Welch’s t-test was used when the variance was
unequal. The paired t-test was used for comparing temporal changes in data.
Univariate and multivariate analyses were performed to determine the
independent factors related to changes in systolic BP, e¢ velocity and E/e¢ with
changes from ACEi or ARB to losartan/HCTZ. Differences in the categorical
data were analyzed by a w2 test and Fisher’s exact test was used when
appropriate. Differences were considered to be statistically signiﬁcant when
P-values were o0.05.
RESULTS
After echocardiographic screening, 415 patients with a history of
treated or untreated hypertension were enrolled in this study between
October 2008 and November 2009. Forty-four patients were excluded
from this study, including 32 patients who were lost to follow-up, 7
patients who were excluded for protocol violation, 3 patients who
were excluded for poor adherence and 2 patients who were excluded
for atrial ﬁbrillation at follow-up. Follow-up study was completed in
371 (89%) of the patients. Baseline characteristics, medication use and
echocardiographic parameters before changing to losartan/HCTZ are
shown in Table 1. The average interval between baseline and follow-up
was approximately 6 months (range, 133–308 days). No patients died,
Table 1 Baseline demographic and clinical characteristics of study
patients
Variables Population (n¼371)
Mean age (s.d.), years 67.5 (9.6)
Women, n (%) 135 (36)
Mean SBP (s.d.), mmHg 155 (15)
Mean DBP (s.d.), mmHg 87 (11)
Mean pulse (s.d.), b.p.m. 73 (11)
Weight (s.d.), kg 64.8 (11.4)
Body mass index (s.d.), kgm 2 25.3 (3.4)
NYHA functional class
Class I, n (%) 228 (61.5)
Class II, n (%) 138 (37.2)
Class III, n (%) 5 (1.3)
Diabetes, n (%) 106 (28.6)
Myocardial infarction, n (%) 19 (5.1%)
Mean eGFR (s.d.), mlmin 1 per 1.73m2 68.7(17.7)
Antihypertensive medication, n (%)
ARB, n (%) 324 (87.3)
ACEi, n (%) 47 (12.7)
Other hypertensive medications, n (%)
Calcium channel blocker, n (%) 171 (46.9)
Beta-blocker, n (%) 89 (24.0)
Alpha-blocker, n (%) 12 (3.2)
Echocardiographic parameters
LVDd (s.d.), mm 47.4 (0.45)
LVDs (s.d.), mm 29.5 (0.45)
Septal wall thickness (s.d.), mm 10.0 (1.6)
LVMI (s.d.), gm 2 102 (22)
LA dimension, mm 40.9 (8.1)
LA volume index, (s.d.), mlm 2 25.4 (9.3)
LVEF (s.d.), % 67.2 (9.1)
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; bpm, beats per minute; DBP, diastolic blood pressure; eGFR, estimated glomerular
ﬁltration rate; LA, left atrial; LVDd, left ventricular end-diastolic dimension; LVDs, left
ventricular end-systolic dimension; LVEF, left ventricular ejection fraction; LVMI, left ventricular
mass index; SBP, systolic blood pressure; s.d., standard deviation.
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hospital in the course of the study.
The effect of change from ACEi or ARB to losartan/HCTZ on BP,
echocardiographic parameters and laboratory data
At follow-up, the mean systolic and diastolic BPs and pulse pressure
decreased from baseline by 23, 11 and 12mmHg, respectively
(Table 2). Heart rate decreased by 2 beatsmin 1. Additional hyper-
tensive medications were given to only 26 patients (7%) and the
medications given to most patients were calcium channel blockers (24
patients (6.5%)). The LV wall thickness, LV mass index and left atrial
volume were signiﬁcantly decreased 6 months after changing to
losartan/HCTZ. There were no changes in peak E, deceleration time
or E/A ratio. The e¢ velocity signiﬁcantly increased (5.5–6.5cms 1,
Po0.0001), implying an improvement in LVrelaxation. The E/e¢ ratio
signiﬁcantly decreased, from 12.1 to 10.6 at follow-up (Po0.0001),
indicating a decrease in LV preload. IVRT also decreased signiﬁcantly
(120–113ms, Po0.0001). Although there was no change in the LV
ejection fraction after changing to losartan/HCTZ, s¢ velocity signiﬁ-
cantly increased, suggesting improvement in LV long-axis contractile
function.
BNP levels decreased after changing from ACEi or ARB to losartan/
HCTZ (48.6 vs. 36.6pgdl 1, P¼0.0006). Interestingly, hsCRP levels
showed a signiﬁcant reduction after changing to losartan/HCTZ.
Urine albumin concentrations also decreased at follow-up. Micro-
albuminemia (X30mg per g Cr) was present in 73 patients (19.7%) at
baseline, but was present in only 49 patients (13.2%) after 6 months of
changing to losartan/HCTZ. There were slight increases in serum
creatinine and blood urea nitrogen, and a slight decrease in the
estimated glomerular ﬁltration rate at follow-up. In all patients, uric
acid did not show a signiﬁcant change after changing to losartan/
HCTZ. In patients with low uric acid levels (o7.0mgdl 1) at baseline
Table 2 Changes in hemodynamic and echocardiographic parameters with changes from ACEi or ARB to losartan/HCTZ
Variables ACEi or ARB 6 months of losartan/HCTZ P-value
SBP, mmHg 155 (15) 132 (12) o0.0001
DBP, mmHg 87 (11) 76 (10) o0.0001
Pulse pressure, mmHg 68 (16) 56 (12) o0.0001
Pulse, b.p.m. 73 (11) 71 (11) 0.0006
Echo parameters
e¢ velocity, cms 1 5.4 (1.4) 6.5 (1.8) o0.0001
s¢ velocity, cms 1 7.7 (2.6) 8.2 (2.6) o0.0001
E/e¢ ratio 12.1 (3.8) 10.6 (3.7) o0.0001
IVRT, ms 120.3 (31.1) 112.7 (27.2) o0.0001
DT, ms 238.3 (54.6) 233.7 (47.8) 0.1214
E velocity, ms 1 64.0 (15.8) 63.9 (14.7) 0.9118
A velocity, ms 1 82.3 (17.7) 79.3 (17.0) o0.0001
E/A ratio 0.80 (0.21) 0.83 (0.22) 0.0013
Septal thickness, mm 10.0 (1.6) 9.7 (1.5) o0.0001
LVEF, % 67.2 (9.1) 67.0 (10.6) 0.6504
LVMI gm 2 102 (22) 96 (22) o0.0001
LA volume index, mlm 2 25.4 (9.3) 23.6 (8.7) o0.0001
Laboratory data
BNP, pgdl 1 48.6 (73.2) 36.6 (55.7) 0.0006
HsCRP, mgdl 1 0.50 (0.62) 0.29 (0.73) o0.0001
Urine albumin, mg per g Cr 71.8 (219.6) 47.0 (228.3) 0.0010
BUN, mgdl 1 17.0 (4.5) 18.2 (5.3) o0.0001
Serum creatinine, mgdl 1 0.83 (0.24) 0.86 (0.25) 0.0001
eGFR, mlmin 1 68.7(17.7) 66.6 (18.3) 0.0001
Uric acid, mgdl 1 (all) 5.9 (1.4) 6.0 (1.5) 0.7318
Uric acid (o7.0), mgdl 1 5.3 (1.0) 5.6 (1.4) o0.0001
Uric acid (X7.0), mgdl 1 7.7 (0.7) 6.9 (1.2) o0.0001
Na, mEqdl 1 141.7 (1.9) 141.3 (2.4) 0.0032
K, mEqdl 1 4.3 (0.4) 4.1 (0.4) o0.0001
Cl, mEqdl 1 104.0 (2.4) 103.0 (3.1) o0.0001
Fasting BS, mgdl 1 111.1 (26.8) 110.9 (28.2) 0.8732
HbA1c, % 6.19 (0.74) 6.14 (0.75) 0.2368
HOMA-R 3.73 (5.01) 3.53 (4.61) 0.5218
Total cholesterol, mgdl 1 202 (31) 195 (31) o0.0001
HDL cholesterol, mgdl 1 55 (14) 54 (14) 0.0011
Triglyceride, mgdl 1 157 (108) 141 (66) 0.0004
Abbreviations: BNP, brain natriuretic peptide; BS, blood sugar; BUN, blood urea nitrogen; Cr, creatinine; DBP,diastolic blood pressure; DT, deceleration time; eGFR, estimated glomerular ﬁltration
rate; HDL, high density lipoprotein; hsCRP, high sensitivity C-reactive protein; IVRT, isovolumetric relaxation time; LA, left atrial; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass
index; SBP, systolic blood pressure
All values are expressed as the mean (s.d.).
HOMA-R: (IRI*FBS/405).
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level (X7.0mgdl 1) at baseline. There were no changes in fasting
glucose levels, hemoglobin A1c, fasting insulin levels or homeostasis
model assessment insulin resistance (HOMA-R) after changing to
losartan/HCTZ.
Factors related to changes in e¢ velocity and E/e¢ ratio
We studied the impact of the magnitude of reduction in systolic BP
with drug changes on e¢ velocity and the E/e¢ ratio. A greater reduction
in systolic BP was associated with a greater increase in e¢ velocity and a
greater reduction in the E/e¢ ratio (Figure 1). There was a close
relationship between changes in s¢ velocity and changes in e¢ velocity
(Figure 2).
We analyzed baseline factors related to the magnitude of changes in
systolic BP, e¢ velocity and the E/e¢ ratio with a change from ACEi or
ARB to losartan/HCTZ (Table 3). The factors included age, sex,
diabetes, body mass index, New York Hypertension Association
(NYHA) class, systolic BP, pulse pressure, heart rate, hsCRP,
HOMA-R, BNP, estimated glomerular ﬁltration rate, LV mass index,
left atrial volume index and microalbuminemia. Multivariate analysis
showed that baseline systolic BP and NYHA class were independent
factors (Po0.05) related to the magnitude of reduction in systolic BP
after changing to losartan/HCTZ. Multivariate analysis also showed
that age, body mass index, NYHA class, systolic BP and hsCRP were
independent factors related to changes in e¢ velocity after changing to
losartan/HCTZ. NYHA class, systolic BP and hsCRP were indepen-
dent factors related to the magnitude of changes in the E/e¢ ratio after
changing to losartan/HCTZ.
As baseline hsCRP is an independent factor related to changes in e¢
velocity and the E/e¢ ratio, we compared temporal changes in these
parameters in patients with high hsCRP (X2.0mgdl 1) and those
with low hsCRP (o0.2mgdl 1) (Figure 3). Reductions in the E/e¢
ratio and increases in e¢ velocity were greater in patients with high
hsCRP at baseline. We studied the impact of NYHA class on changes
in e¢ velocity and the E/e¢ ratio after changing to losartan/HCTZ. Our
data showed that increases in e¢ velocity and decreases in the E/e¢ ratio
were greater in patients with NYHA class 2 or 3 than in patients with
NYHA class 1.
Adverse events. Adverse events were observed in 22 patients. The
adverse events included photosensitivity or skin eruption (11
patients), dizziness (5 patients), general fatigue (4 patients), an
increase in BP (1 patient) and worsening of renal function (1 patient).
Losartan/HCTZ was withdrawn in 14 patients and they were dropped
from the study.
DISCUSSION
We showed that changes from ACEi or ARB to losartan/HCTZ further
lowered BP, improved LV relaxation (an increase in e¢ velocity),
reduced LV preload (a decrease in the E/e¢ ratio), and improved HF
state (a decrease in BNP) in patients with hypertension and diastolic
dysfunction. The drug change was also associated with reductions in
hsCRP. We ﬁrst documented that the change from ACEi or ARB to
losartan/HCTZ could improve LV relaxation and HF in patients with
diastolic dysfunction, and that these improvements were associated
with attenuation of systemic inﬂammation.
The optimization of hemodynamics is achieved primarily by redu-
cing cardiac preload and afterload in patients with diastolic dysfunc-
tion. An ACEi or ARB may affect myocardial relaxation and
compliance by reducing BP and arterial stiffness and by reducing
interstitial collagen deposition, but it cannot reduce LV preload.
Diuretics are effective for reducing LV preload. Our results showed
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reduction of the E/e¢ ratio and an increase in e¢ velocity. A decrease in
IVRT after the drug change also suggests an improvement in LV
relaxation. IVRT is sensitive to LV preload and relaxation. In the case
of reduced preload, IVRT decreases only when LVrelaxation improves,
as shown in this study. The combination of improvement in LV
relaxation and a decrease in preload can be attributed to a reduced left
atrial volume index and BNP level at follow-up.
There are several mechanisms by which e¢ velocity can increase with
changes from ACEi or ARB to losartan/HCTZ. Reductions in systolic
BP themselves can be associated with increases in e¢ velocity.9–11 The
CALVLOC (Clinical Impact of Azelnidipine on Left VentricuLar
Diastolic Function and OutComes in Patients with Hypertension)
trial documented that a reduction in systolic BP with a calcium
channel blocker, azelnidipine, was associated with an increase in e¢
velocity.10 This study showed that a greater increase in s¢ velocity after
changing to losartan/HCTZwas associated with a greater increase in e¢
velocity. Many patients with diastolic dysfunction may have subtle
abnormalities of systolic contractile function. The LV longitudinal
contractile function is a primary contributor to LV pumping and is
particularly sensitive to the effects of afterload.12 It is speculated that
further reduction in afterload with losartan/HCTZ can improve LV
longitudinal contractile function (an increase in s¢ velocity), resulting
in improvement of LVrelaxation. Reduction of the LV mass index can
also contribute to improvement in LV relaxation.13
In this study, hsCRP signiﬁcantly decreased with changes from
ACEi or ARB to losartan/HCTZ. CRP level is a marker of systemic
inﬂammation. Higher levels of CRP are associated with higher BP.14
CRP levels are also elevated in patients with diastolic dysfunction, and
they correlate with disease severity, as well as LV preload.15 The
mechanism of CRP elevation in patients with diastolic dysfunction
has not been elucidated. Organ congestion and hypoperfusion might
inﬂuence the secretion of interleukin-6 by hepatic, renal, endothelial,
mononuclear and even cardiac myocytes.16 Elevated inﬂammatory
markers have been associated with an increased risk of developing
symptomatic HF.17 CRP may be an active participant in the develop-
ment of diastolic dysfunction. CRP can inhibit nitric oxide produc-
tion, impede endothelial function and activate the complement
cascade.18 Interleukin-6, which affects CRP, has been shown to
promote myocyte hypertrophy.19 Reductions in BP and LV preload
with changes to losartan/HCTZ may contribute to a reduction in CRP.
Therefore, the attenuation of the systemic inﬂammatory response with
changes to losartan/HCTZ may contribute to the improvement of LV
diastolic function.
Table 3 Predictors of changes in SBP, e¢ velocity and E/e¢ ratio after changing from ACEi or ARB to losartan/HCTZ
Changes in SBP Changes in e¢ velocity Changes in E/e¢ ratio
Univariate analysis
P-value
Multivariate analysis
P-value
Univariate analysis
P-value
Multivariate analysis
P-value
Univariate analysis
P-value
Multivariate analysis
P-value
Age 0.9693 0.0009 0.0001 0.0923
BMI 0.0994 0.0281 0.0065 0.0341 0.2024
NYHA 1 vs. 2 or 3 0.0000 0.0030 0.0000 0.0000 0.0000 0.0010
SBP 0.0000 0.0000 0.0000 0.0043 0.0000 0.0189
HsCRP 0.0000 0.9939 0.0000 0.0001 0.0000 0.0000
Abbreviations: BMI, body mass index; HCTZ, hydrochlorothiazide; hsCRP, high sensitivity C-reactive protein; NYHA, New York hypertension association; SBP, systolic blood pressure
hsCRP<0.2 mg/dl hsCRP>0.2 mg/dl
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index,21 the LV mass index22 and hsCRP are useful for risk stratiﬁca-
tion in patients with HF. A lower BNP, left atrial volume index or LV
mass index is associated with better clinical outcomes, and lower rates
of morbidity and mortality. These parameters are now regarded as
excellent surrogate end points for assessing the utility of therapeutic
interventions. Our results showed that BNP, the left atrial volume
index and the LV mass index signiﬁcantly decreased with changes
from ACEi or ARB to losartan/HCTZ. Therefore, the combination of
an ARB and a small dose of thiazide might be a good therapeutic
choice for reducing hospitalization due to HF, and mortality in
patients with hypertension and diastolic dysfunction.
Much of the criticism against thiazides has been directed toward
their adverse-effect proﬁle. Thiazides can reduce the excretion of uric
acid and thereby increase its plasma level. Our results, however,
showed that there was no change in uric acid levels with changes
from ACEi or ARB to losartan/HCTZ. This ﬁnding was because of the
potential of losartan to augment the excretion of uric acid.23 Some
patients with diastolic dysfunction are sensitive to preload reduction
and may develop severe pre-renal azotemia. In this study, blood urea
nitrogen and creatinine levels showed only slight increases with
changes to losartan/HCTZ. New-onset diabetes has been reported in
patients receiving thiazides.24 Maintaining potassium homeostasis is
essential because epidemiologic evidence implicates hypokalemia in
the pathogenesis of thiazide-induced dysglycemia.25 In this study,
there were no changes in potassium levels or levels of blood glucose,
HbA1c, serum insulin and HOMA-R after changing to losartan/
HCTZ.
Limitations
Some limitations should be noted. This study was a single-arm trial.
The main objective of this study was not to monitor clinical outcomes,
but to detect changes in objective parameters to assess the change
made upon LV diastolic function after changing from ACEi or ARB to
losartan/HCTZ. We did not simply add a small dose of HCTZ to each
ACEi or ARB, but changed them to losartan/HCTZ to improve patient
adherence. Only three patients dropped out because of poor adher-
ence. Most of the patients were mildly to moderately hypertensive and
without clinical HF. The ﬁndings in this study may not be applicable
to patients with severe diastolic dysfunction. In this study, however,
the magnitude of increase in e¢ velocity was greater and the magnitude
of decrease in the E/e¢ ratio was also greater in patients with
symptomatic HF. It is not clear whether an increase in e¢ velocity by
1.0cms 1 or decrease in the E/e¢ ratio by 1.5 is clinically meaningful
or whether it would be associated over time with improvement in
outcomes.
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